NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT03516279 2026-03-02
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05456191 2026-02-06
ASC4START
Novartis
Phase 3 Active not recruiting
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT02917720 2025-09-22
NAUT
European LeukemiaNet
Phase 2 Active not recruiting
NCT03906292 2025-03-10
CMLXI
University of Jena
Phase 2 Active not recruiting
NCT04147533 2024-11-26
HALF
Masaryk University
Phase 2 Active not recruiting